6901.TW DIAMOND BIOFUND INC
- Market cap
- TWD 12.2B
- P/E
- 4.3x
- P/B
- 0.99x
- ROE
- 50.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6901.TW undervalued?
Graham number6901.TW trades 56.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DIAMOND BIOFUND INC fundamental analysis
No fundamental analysis for DIAMOND BIOFUND INC yet.
DIAMOND BIOFUND INC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.
Full company profileDIAMOND BIOFUND INC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DIAMOND BIOFUND INC annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | - | - | - | - | - | -596K | 6.26B |
| Gross Profit | - | - | - | - | - | - | -28.6M | 6.26B |
| Operating Income | -368M | 6.10B | -102M | -138M | -162M | -181M | -1.28B | 6.11B |
| EBITDA | -53.9M | 6.13B | 2.97B | 893M | -2.57B | -2.36B | -1.14B | 6.19B |
| Net Income | -371M | 6.09B | 2.85B | 798M | -2.58B | -2.52B | -1.17B | 6.17B |
| EPS | -0.55 | 6.10 | 2.99 | 1.03 | -3.32 | -2.96 | -1.38 | 7.09 |
| Balance Sheet | ||||||||
| Total Assets | 3.08B | 9.28B | 10.6B | 11.2B | 13.0B | 10.7B | 9.36B | 12.4B |
| Total Liabilities | 68.7M | 180M | 231M | 144M | 180M | 302M | 138M | 126M |
| Shareholders' Equity | 3.01B | 9.10B | 10.4B | 11.1B | 12.9B | 10.4B | 9.22B | 12.3B |
| Cash & Short-term Investments | 1.26B | 8.15B | 10.1B | 10.7B | 9.65B | 5.13B | 3.89B | 2.53B |
| Total Debt | 61.5M | 50.6M | 42.0M | 3.67M | 129M | 118M | 93.9M | 81.7M |
| Cash Flow | ||||||||
| Operating Cash Flow | -39.6M | -73.0M | -300M | 473M | -196M | 1.14B | -166M | -69.9M |
| Capital Expenditure | 1.48M | 0.00 | 0.00 | 2.05M | 19.5M | 14.2M | 189K | 0.00 |
| Free Cash Flow | -41.1M | -73.0M | -300M | 471M | -215M | 1.12B | -166M | -69.9M |
| Ratios | ||||||||
| ROE | -12.3% | 66.9% | 27.4% | 7.2% | -20.1% | -24.3% | -12.7% | 50.1% |
| ROA | -12.0% | 65.6% | 26.8% | 7.1% | -19.8% | -23.6% | -12.6% | 49.6% |
| Net Profit Margin | - | - | - | - | - | - | - | 98.5% |
| Debt to Equity | 0.02x | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DIAMOND BIOFUND INC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 7, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | TWD 127M | 0.16 | - |
| 2022 | TWD 150M | 0.19 | 18.8% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1180:1000 on Aug 7, 2023.
Who owns DIAMOND BIOFUND INC
- Insiders 83.63%
- Institutions 0.03%
- Public & others 16.34%
- Shares outstanding 853M
- Free float 177M
DIAMOND BIOFUND INC company profile
- Company name
- DIAMOND BIOFUND INC
- Ticker
- 6901.TW
- ISIN
- TW0006901002
- Exchange
- Taiwan Stock Exchange
- Sector
- Financial Services
- Industry
- Asset Management
- Employees
- 29
- Fiscal year end
- December
- Address
- 34th Floor, Taipei, Taiwan, 100
- Phone
- 886 2 2703 1338
About DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.
DIAMOND BIOFUND INC management
5- Mr. Kung-Ming LuGeneral Manager
- Ms. You-Mei WuChairman's Office Supervisor · born 1964
- Ms. Chin-Ling LuAssistant Vice President
- Ms. Yuehlin KuoFinancial Officer
- Junru JianAccounting supervisor